Aravive, Inc. (ARAV)
| Market Cap | 88.66M |
| Revenue (ttm) | 5.94M |
| Net Income (ttm) | -27.75M |
| Shares Out | 18.07M |
| EPS (ttm) | -1.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $4.14 |
| Previous Close | $4.34 |
| Change ($) | -0.20 |
| Change (%) | -4.61% |
| Day's Open | 4.35 |
| Day's Range | 4.12 - 4.40 |
| Day's Volume | 77,328 |
| 52-Week Range | 3.97 - 9.95 |
HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gai...
Milestone is Based on Approval of 3D Medicines' IND in China to Participate in Aravive's AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer Milestone is Based on Approval of 3...
HOUSTON, July 07, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gai...
Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Addresses High Unmet Medical Need for Women with Advanced Ovarian Cancer
HOUSTON, March 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq:ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that updated data from its Phase 1b tri...
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities p...
HOUSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will present at the H.C. Wa...
HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be steppin...
Aravive is drugging the GAS6-AXL pathway to develop new medicines across several cancer indications. Early clinical data has established safety for the company's lead drug candidate, AVB-500, and early ...
HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual Ovarian...
HOUSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financial ...
Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer (PROC) Strengthens Advisory Team with Industry Veteran as Company Advances AVB-500 in Pla...
HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industry veteran ...
HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and co...
Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Platinum Resistant Ovarian Cancer Expands Clinical Development and Oncology Expertise as Company Advances AVB-500 in Pl...
HOUSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced recent corporate updates and financia...
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and con...
Identifies Recommended Phase 2 Dose for Continued Clinical Development of AVB-500 in Platinum Resistant Ovarian Cancer
HOUSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases,...
Investors have had a love affair with the market around underwritten initial public offerings for many years, but the other side of the underwriting world revolves around secondary offerings and capital...
In the latest trading session, Aravive (ARAV) closed at $14.11, marking a -1.47% move from the previous day.
Aravive (ARAV) closed at $13.55 in the latest trading session, marking a -0.88% move from the prior day.
Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Aravive (ARAV) closed at $11.96, marking no change from the previous day.
HOUSTON and SHANGHAI, April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with lead...
Aravive (ARAV) closed at $13.82 in the latest trading session, marking a +0.88% move from the prior day.
Is (ARAV) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in Aravive.
Top Ranked Momentum Stocks to Buy for April 20th
Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Aravive (ARAV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Healthcare Entrepreneur Fred Eshelman, Pharm.D., Appointed Board Chairman
HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored Phase...
Rekha Hemrajani Appointed President, Chief Executive Officer and Director to Execute Corporate Strategy as Company Advances Clinical Pipeline
HOUSTON, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that the company has begun enrolling patients in the Phase 2a clini...
Investors need to pay close attention to Aravive (ARAV) stock based on the movements in the options market lately.
HOUSTON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threateni...
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threateni...
Aravive Inc. (NASDAQ: ARAV) shares skyrocketed on Wednesday after the firm announced early-stage data for its ovarian cancer treatment.
Aravive stock doubled in value Wednesday after the biotech company delivered bullish test results for a high-dose ovarian cancer treatment vs. a lower dose of the same experimental medicine.
Shares of Aravive ARAV, +3.40% are up 270% in premarket trading Wednesday after the Houston-based biotech reported positive data from an early-stage clinical trial.
Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity
About ARAV
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to blo... [Read more...]
| Industry Biotechnology | IPO Date Mar 21, 2014 |
| CEO Gail McIntyre | Employees 17 |
| Stock Exchange NASDAQ | Ticker Symbol ARAV |
Financial Performance
In 2020, Aravive's revenue was $5.69 million, an increase of 19.61% compared to the previous year's $4.75 million. Losses were -$30.54 million, 67.7% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Aravive stock is "Buy." The 12-month stock price forecast is 22.50, which is an increase of 443.48% from the latest price.